功能性LTCC-βAR复合体需要caveolin-3并且在心力衰竭中受到干扰
Jose L Sanchez-Alonso1, Laura Fedele1, Jaël S Copier1
1National Heart and Lung Institute, Imperial College London, United Kingdom (J.L.S.-A., L.F., J.S.C., C.L., C.M., A.J., T.B., J.G.).
Circulation research
|June 14, 2023
概括
贝塔-2上腺素受体 (β2ARs) 与心肌细胞中的L型Ca2+通道 (LTCCs) 形成功能复合体,但这种合在心力衰竭中丢失. 这项研究揭示了β2AR-LTCC近距离信号对健康的心脏功能至关重要.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 细胞生理学 细胞生理学
背景情况:
- β2上腺素受体 (β2ARs),但非β1上腺素受体 (β1ARs),在心肌细胞膜上与L型Ca2+通道 (LTCCs) 形成功能综合体.
- 微域定位对这些βAR-LTCC复合体的功能的影响在很大程度上是未知的.
- 了解这些相互作用对于调查心力衰竭中障碍至关重要.
研究的目的:
- 调查LTCCs与不同心肌细胞微域内的β上腺素受体 (βARs) 之间的合.
- 阐明PKA和CaMKII在这个功能复合体中的作用.
- 探索如何在心力衰竭的背景下破坏这个复合体.
主要方法:
- 使用全细胞电流记录和西部斑分析来评估LTCC和βAR之间的全球信号.
- 超分辨率扫描补丁可以在不同的膜微域中探索单个LTCC和β1AR或β2AR之间的局部合.
- 分析包括来自动物和人类的控制和失败的心肌细胞,以及用Caveolin-3敲击的小鼠模型.
主要成果:
- 在横管微域中局部刺激β2ARs (<350 nm) 将LTCC的开放概率 (Po) 从0.054±0.003增加到0.092±0.008.
- 这种β2AR-LTCC合在动物和人类失败的心肌细胞中不存在.
- 局部β1AR刺激没有改变LTCC Po,尽管通过β1AR的全球激活增加了LTCC电流,主要涉及PKA;β2AR-LTCC调节需要高-3和CaMKII激活.
结论:
- 通过近距离合来调节LTCC活动,完全通过β2ARs而不是β1ARs调节健康心脏中的上腺素反应.
- 这种关键的β2AR-LTCC合在心力衰竭中丢失.
- 恢复这种近距离合可能提供一种治疗策略,以改善衰竭心肌细胞中的上腺反应.
相关概念视频
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
17
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
01:23Cystic Fibrosis: Pathogenesis
301
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
301
01:22Heart Failure Drugs: β-Blockers
382
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
382